Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial
- 12 May 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (4), euw064-606
- https://doi.org/10.1093/europace/euw064
Abstract
Aims To conduct a randomized trial in order to guide the optimum therapy of symptomatic atrioventricular nodal re-entrant tachycardia (AVNRT). Methods and results Patients with at least one symptomatic episode of tachycardia per month and an electrophysiologic diagnosis of AVNRT were randomly assigned to catheter ablation or chronic antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem (120–300 mg od). All patients were properly educated to treat subsequent tachycardia episodes with autonomic manoeuvres or a ‘pill in the pocket’ approach. The primary endpoint of the study was hospital admission for persistent tachycardia cardioversion, during a follow-up period of 5 years. Sixty-one patients were included in the study. In the ablation group, 1 patient was lost to follow-up, and 29 were free of arrhythmia or conduction disturbances at a 5-year follow-up. In the AAD group, three patients were lost to follow-up. Of the remainder, 10 patients (35.7%) continued with initial therapy, 11 patients (39.2%) remained on diltiazem alone, and 7 patients (25%) interrupted their therapy within the first 3 months following randomization, and subsequently developed an episode requiring cardioversion. During a follow-up of 5 years, 21 patients in the AAD group required hospital admission for cardioversion. Survival free from the study endpoint was significantly higher in the ablation group compared with the AAD group (log-rank test, P < 0.001). Conclusions Catheter ablation is the therapy of choice for symptomatic AVNRT. Antiarrhythmic drug therapy is ineffective and not well tolerated.Keywords
This publication has 19 references indexed in Scilit:
- Gender-related differences in outcomes and resource utilization in patients undergoing radiofrequency ablation of supraventricular tachycardia: results from Patients' Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT StudyEP Europace, 2014
- Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placeboAmerican Heart Journal, 2001
- Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardiaJournal of the American College of Cardiology, 2001
- Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmiasAmerican Heart Journal, 1997
- A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardiaThe American Journal of Cardiology, 1996
- Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmiasEuropean Heart Journal, 1995
- Flecainide acetate for paroxysmal supraventricular tachyarrhythmiasThe American Journal of Cardiology, 1994
- Antiarrhythmic actions of diltiazem during experimental atrioventricular reentrant tachycardias. Importance of use-dependent calcium channel-blocking properties.Circulation, 1990
- Long-term therapy of paroxysmal supraventricular tachycardia: A randomized, double-blind comparison of digoxin, propranolol and verapamilThe American Journal of Cardiology, 1984
- Oral Verapamil for Paroxysmal Supraventricular TachycardiaAnnals of Internal Medicine, 1982